BE2014C051I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2014C051I2 BE2014C051I2 BE2014C051C BE2014C051C BE2014C051I2 BE 2014C051 I2 BE2014C051 I2 BE 2014C051I2 BE 2014C051 C BE2014C051 C BE 2014C051C BE 2014C051 C BE2014C051 C BE 2014C051C BE 2014C051 I2 BE2014C051 I2 BE 2014C051I2
- Authority
- BE
- Belgium
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Oncology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39871102P | 2002-07-25 | 2002-07-25 | |
PCT/EP2003/050322 WO2004011436A1 (fr) | 2002-07-25 | 2003-07-18 | Derives de quinoleine et leur utilisation en tant qu'inhibiteurs mycobacteriens |
EP03771115A EP1527050B1 (fr) | 2002-07-25 | 2003-07-18 | Derives de quinoleine et leur utilisation en tant qu'inhibiteurs mycobacteriens |
Publications (1)
Publication Number | Publication Date |
---|---|
BE2014C051I2 true BE2014C051I2 (fr) | 2022-08-09 |
Family
ID=31188461
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE2014C051C BE2014C051I2 (fr) | 2002-07-25 | 2014-08-14 |
Country Status (38)
Country | Link |
---|---|
US (1) | US7498343B2 (fr) |
EP (2) | EP1527050B1 (fr) |
JP (1) | JP4484703B2 (fr) |
KR (1) | KR100733577B1 (fr) |
CN (2) | CN101070304B (fr) |
AP (1) | AP2421A (fr) |
AR (1) | AR040673A1 (fr) |
AT (1) | ATE463482T1 (fr) |
AU (1) | AU2003262529B2 (fr) |
BE (1) | BE2014C051I2 (fr) |
BR (1) | BRPI0312927B8 (fr) |
CA (1) | CA2493225C (fr) |
CY (3) | CY1111882T1 (fr) |
DE (1) | DE60332023D1 (fr) |
DK (2) | DK1527050T3 (fr) |
EA (1) | EA008937B1 (fr) |
ES (2) | ES2395237T3 (fr) |
FR (1) | FR14C0060I2 (fr) |
HK (2) | HK1083496A1 (fr) |
HR (2) | HRP20050045B1 (fr) |
HU (1) | HUS1400047I1 (fr) |
IL (2) | IL166457A (fr) |
IS (1) | IS2914B (fr) |
LU (1) | LU92520I2 (fr) |
ME (1) | ME00131B (fr) |
MX (1) | MXPA05001052A (fr) |
MY (1) | MY143564A (fr) |
NL (1) | NL300684I2 (fr) |
NO (2) | NO329935B1 (fr) |
NZ (1) | NZ538391A (fr) |
PL (1) | PL222801B1 (fr) |
PT (2) | PT1527050E (fr) |
RS (1) | RS52431B (fr) |
SI (2) | SI2301544T1 (fr) |
TW (1) | TWI323730B (fr) |
UA (1) | UA82198C2 (fr) |
WO (1) | WO2004011436A1 (fr) |
ZA (1) | ZA200500680B (fr) |
Families Citing this family (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1711181E (pt) * | 2004-01-23 | 2009-12-29 | Janssen Pharmaceutica Nv | Derivados quinolina e sua utilização como inibidores micobacterianos |
AP2188A (en) | 2004-01-23 | 2010-12-14 | Janssen Pharmaceutica Nv | Substituted quinolines and their use as mycobacterial inhibitors. |
AU2005210036B2 (en) * | 2004-01-29 | 2010-12-23 | Janssen Pharmaceutica N.V. | Quinoline derivatives for use as mycobacterial inhibitors |
EP1753427B1 (fr) * | 2004-05-28 | 2008-04-02 | Janssen Pharmaceutica N.V. | Utilisation de derives substitues de quinoline dans le traitement de maladies mycobacteriennes resistantes aux medicaments |
DK1797115T3 (en) * | 2004-09-28 | 2017-10-02 | Janssen Pharmaceutica Nv | BACTERIAL ATP SYNTHASE BINDING DOMAIN. |
EE05394B1 (et) * | 2004-12-24 | 2011-04-15 | Janssen Pharmaceutica N.V. | Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis |
KR101301573B1 (ko) * | 2004-12-24 | 2013-09-04 | 얀센 파마슈티카 엔.브이. | 잠재성 튜버큐로시스의 치료법 |
JP5410749B2 (ja) | 2005-05-25 | 2014-02-05 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | (アルファs,ベータr)−6−ブロモ−アルファ−[2−(ジメチルアミノ)エチル]−2−メトキシ−アルファ−1−ナフタレニル−ベータ−フェニル−3−キノリンエタノールの製造方法 |
TWI380819B (zh) * | 2005-06-08 | 2013-01-01 | Janssen Pharmaceutica Nv | 用作抗細菌劑之喹啉衍生物 |
CA2528849C (fr) | 2005-06-08 | 2014-01-14 | Janssen Pharmaceutica N.V. | Derives de quinoleine utilises comme agents antibacteriens |
JP5349730B2 (ja) * | 2005-06-09 | 2013-11-20 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 抗バクテリア剤としてのキノリン誘導体 |
EA010601B1 (ru) * | 2005-06-09 | 2008-10-30 | Янссен Фармацевтика Н.В. | Производные хинолина в качестве антибактериальных агентов |
KR101318181B1 (ko) * | 2005-06-09 | 2013-10-16 | 얀센 파마슈티카 엔.브이. | 항균제로서의 퀴놀린 유도체 |
JO3270B1 (ar) * | 2005-06-28 | 2018-09-16 | Janssen Pharmaceutica Nv | مشتقات كوينولين بصفة عوامل مضادة للبكتيريا |
JO2752B1 (en) * | 2005-06-28 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | Quinoline derivatives acting as antibacterial agents |
BRPI0613999B8 (pt) * | 2005-06-28 | 2021-05-25 | Janssen Pharmaceutica Nv | uso de um composto derivado de quinolina, o referido composto, sua combinação, composição farmacêutica, uso da referida combinação, e produto |
JO3077B1 (ar) * | 2005-07-28 | 2017-03-15 | Janssen Pharmaceutica Nv | مشتقات كوينولين مضادة للبكتيريا |
JO2855B1 (en) * | 2005-08-03 | 2015-03-15 | شركة جانسين فارماسوتيكا ان. في | Quinoline derivatives acting as antibacterial agents |
JO2952B1 (en) * | 2005-08-03 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Quinoline derivatives acting as antibacterial agents |
JO2837B1 (en) * | 2005-08-03 | 2014-09-15 | جانسن فارمسيتكا ان في | Quinoline derivatives acting as antibacterial agents |
EP1917245A1 (fr) * | 2005-08-21 | 2008-05-07 | Abbott GmbH & Co. KG | Composes heterocycliques et leur utilisation en tant que partenaires de liaison des recepteurs 5-ht5 |
DE102005044817A1 (de) | 2005-09-20 | 2007-03-22 | Sanofi-Aventis Deutschland Gmbh | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
UA97813C2 (uk) * | 2006-12-05 | 2012-03-26 | Янссен Фармацевтика Н.В. | Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу |
JO3271B1 (ar) | 2006-12-06 | 2018-09-16 | Janssen Pharmaceutica Nv | مشتقات الكوينولين المضادة للجراثيم |
JO2725B1 (en) * | 2006-12-06 | 2013-09-15 | جانسين فارماسوتيكا ان. في | Quinoline antibacterial derivatives |
JO2685B1 (en) * | 2006-12-06 | 2013-03-03 | جانسين فارماسوتيكا ان في | Quinoline antibacterial derivatives |
JO2970B1 (en) * | 2006-12-06 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Quinoline antibacterial derivatives |
JO2683B1 (en) * | 2006-12-06 | 2013-03-03 | جانسين فارماسوتيكا ان. في | Quinoline antibacterial derivatives |
JO2684B1 (en) * | 2006-12-06 | 2013-03-03 | جانسين فارماسوتيكا ان في | Quinoline antibacterial derivatives |
RU2404971C2 (ru) * | 2008-12-02 | 2010-11-27 | ЗАО "Фарм-Синтез" | Новые производные хинолина, способ их получения, их применение для лечения микобактериальных инфекций, фармацевтическая композиция на их основе |
CN102249935B (zh) * | 2010-05-17 | 2015-05-20 | 中国人民解放军军事医学科学院毒物药物研究所 | 芳香2-丁醇类化合物及其医药用途 |
RU2486175C2 (ru) * | 2011-09-12 | 2013-06-27 | Закрытое Акционерное Общество "Фарм-Синтез" | Производные хинолина, в частности 5,6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ получения и применение соединений |
EA038350B1 (ru) | 2012-04-27 | 2021-08-12 | Янссен Фармацевтика Нв | Антибактериальные хинолиновые производные |
ES2576491T3 (es) | 2012-04-27 | 2016-07-07 | Janssen Pharmaceutica, N.V. | Derivados de quinolina antibacterianos |
US9572809B2 (en) | 2012-07-18 | 2017-02-21 | Spero Trinem, Inc. | Combination therapy to treat Mycobacterium diseases |
UA117672C2 (uk) | 2012-12-21 | 2018-09-10 | ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі | Антибактеріальні сполуки |
RU2530493C1 (ru) * | 2013-04-22 | 2014-10-10 | Закрытое Акционерное Общество "Фарм-Синтез" | Производные хинолина, в частности 6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ их получения и применение соединений для лечения инфекционных заболеваний микобактериальной природы, в частности туберкулеза |
CN105017147B (zh) * | 2014-04-30 | 2019-02-01 | 中国医学科学院药物研究所 | 一种回收和利用Bedaquiline立体化学异构体的方法 |
CN105085395B (zh) * | 2014-05-07 | 2017-09-26 | 国药集团国瑞药业有限公司 | 贝达喹啉的制备方法 |
CN105085396B (zh) * | 2014-05-07 | 2017-08-08 | 国药集团国瑞药业有限公司 | 用于制备贝达喹啉的中间体及其制备方法和应用 |
CN105198808B (zh) * | 2014-05-27 | 2017-08-25 | 北京万生药业有限责任公司 | 一种高效生产贝达喹啉的方法 |
CN105175329B (zh) * | 2014-06-10 | 2017-09-19 | 重庆圣华曦药业股份有限公司 | 一种贝达喹啉消旋体的合成路线及方法 |
CN105330595B (zh) * | 2014-07-14 | 2019-12-10 | 上海嘉坦医药科技有限公司 | 吡啶衍生物及其作为抗分支杆菌的应用 |
BR112017000764B1 (pt) * | 2014-07-14 | 2022-07-12 | Shanghai Jia Tan Pharmatech Co. Ltd. | Composto, método para preparar o composto e uso do composto |
CN105440051B (zh) * | 2014-09-19 | 2019-07-05 | 重庆医药工业研究院有限责任公司 | 一种抗结核的噻吩吡啶衍生物 |
CZ2014708A3 (cs) | 2014-10-16 | 2016-04-27 | Zentiva, K.S. | Soli Bedaquilinu |
CZ201534A3 (cs) | 2015-01-21 | 2016-08-03 | Zentiva, K.S. | Nové možnosti chirální resoluce bedaquilinu |
CZ201533A3 (cs) | 2015-01-21 | 2016-08-03 | Zentiva, K.S. | Způsob izolace směsi enantiomerů |
CZ201535A3 (cs) | 2015-01-21 | 2016-08-03 | Zentiva, K.S. | Nové možnosti chirální resoluce bedaquilinu |
AU2016212116B2 (en) | 2015-01-27 | 2021-07-15 | Janssen Pharmaceutica Nv | Dispersible compositions |
US10674732B2 (en) * | 2015-04-29 | 2020-06-09 | The State Of Israel, Ministry Of Agriculture & Rural Development Agricultural Research Organization | Anti-phytopathogenic compositions |
CN106279017A (zh) * | 2015-05-21 | 2017-01-04 | 重庆圣华曦药业股份有限公司 | 贝达喹啉晶型、组合物及其制备方法 |
CZ2015391A3 (cs) | 2015-06-09 | 2016-12-21 | Zentiva, K.S. | Sůl bedaquilinu s kyselinou citronovou |
MX2017016788A (es) | 2015-07-02 | 2018-07-06 | Janssen Sciences Ireland Uc | Compuestos antibacterianos. |
CN105061387A (zh) * | 2015-07-17 | 2015-11-18 | 苏州大学 | 二芳基醚类稠环类化合物、制备方法和用途 |
CN107848978B (zh) * | 2015-07-24 | 2021-04-02 | 浙江海正药业股份有限公司 | 一种分离贝达喹啉非对映异构体a的方法 |
EP3366676B1 (fr) | 2015-10-20 | 2021-05-26 | Zhejiang Hisun Pharmaceutical Co., Ltd | Formes cristallines de fumarate de bédaquiline et leurs procédés de préparation |
WO2017121323A1 (fr) * | 2016-01-13 | 2017-07-20 | 辰欣药业股份有限公司 | Procédé de préparation d'un composé dérivé de pyridine, intermédiaire et forme cristalline dudit composé |
EP3423449B1 (fr) * | 2016-03-03 | 2021-04-07 | Council of Scientific and Industrial Research | Alcaloïdes d'aurone substitués en tant qu'agents anti-mycobactériens |
US10508097B2 (en) * | 2016-03-07 | 2019-12-17 | The Global Alliance For Tb Drug Development, Inc. | Antibacterial compounds and uses thereof |
JP2019518050A (ja) | 2016-06-16 | 2019-06-27 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | 抗菌薬としての複素環式化合物 |
EA201990043A1 (ru) | 2016-06-16 | 2019-05-31 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Антибактериальные соединения |
CN110831630A (zh) | 2017-03-01 | 2020-02-21 | 爱尔兰詹森科学公司 | 组合疗法 |
WO2019012100A1 (fr) * | 2017-07-14 | 2019-01-17 | Janssen Pharmaceutica Nv | Formulations à action prolongée |
CN109384716B (zh) * | 2017-08-11 | 2021-06-29 | 海创药业股份有限公司 | 一种氘代喹啉化合物及其制备和用途 |
JP2022516671A (ja) | 2019-01-09 | 2022-03-01 | ヤンセン ファーマシューティカ エヌ.ベー. | 非結核性抗酸菌症の処置における組合せ |
WO2020161743A1 (fr) | 2019-02-08 | 2020-08-13 | Mylan Laboratories Limited | Procédé de préparation de fumarate de bédaquiline |
WO2021048342A1 (fr) | 2019-09-13 | 2021-03-18 | Janssen Sciences Ireland Unlimited Company | Composés antibactériens |
WO2021057190A1 (fr) * | 2019-09-29 | 2021-04-01 | 上海阳帆医药科技有限公司 | Composés quinoléine, leur procédé de préparation et utilisation associée |
EP4038069A1 (fr) | 2019-09-30 | 2022-08-10 | Janssen Sciences Ireland Unlimited Company | Composés antibactériens |
BR112022005068A2 (pt) | 2019-09-30 | 2022-09-06 | Janssen Sciences Ireland Unlimited Co | Compostos antibacterianos de 4-quinolinona |
CN110804016B (zh) * | 2019-12-05 | 2022-11-04 | 福建省微生物研究所 | 抗结核分枝杆菌的二芳基喹啉衍生物 |
BR112022012704A2 (pt) | 2019-12-27 | 2022-09-06 | Tecnimede Soc Tecnico Medicinal Sa | Quinolinas antibacterianas. |
KR102303635B1 (ko) | 2020-07-01 | 2021-09-17 | 동아에스티 주식회사 | (1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법 |
JP2023532981A (ja) | 2020-07-09 | 2023-08-01 | ヤンセン ファーマシューティカ エヌ.ベー. | 長時間作用型配合物 |
JP2023532982A (ja) | 2020-07-09 | 2023-08-01 | ヤンセン ファーマシューティカ エヌ.ベー. | 長時間作用型配合物 |
US20230241051A1 (en) | 2020-07-09 | 2023-08-03 | Janssen Pharmaceutica Nv | Long-acting formulations |
CN116406270A (zh) | 2020-11-12 | 2023-07-07 | 詹森药业有限公司 | 在治疗非结核分枝杆菌疾病时的贝达喹啉、乙胺丁醇和大环内酯的组合 |
AU2022237769A1 (en) | 2021-03-16 | 2023-11-02 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
AU2022240967A1 (en) | 2021-03-17 | 2023-11-02 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
US20240182495A1 (en) | 2021-03-17 | 2024-06-06 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
WO2022214520A1 (fr) | 2021-04-07 | 2022-10-13 | Janssen Sciences Ireland Unlimited Company | Composés antibactériens |
WO2022214519A1 (fr) | 2021-04-07 | 2022-10-13 | Janssen Sciences Ireland Unlimited Company | Composés antibactériens |
CA3223626A1 (fr) | 2021-06-29 | 2023-01-05 | Augusto Eugenio Pardal Filipe | Composes heterocycliques pour le traitement de la tuberculose |
TW202325274A (zh) | 2021-10-28 | 2023-07-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | 抗菌化合物 |
WO2023150747A1 (fr) | 2022-02-07 | 2023-08-10 | Insmed Incorporated | Compositions de poudre sèche de bédaquiline et de sels et leurs méthodes d'utilisation |
CN114835641B (zh) * | 2022-05-07 | 2024-03-15 | 南京杰运医药科技有限公司 | 一种3-苄基-6-溴-2-甲氧基喹啉的合成方法 |
CN117050006A (zh) * | 2022-05-13 | 2023-11-14 | 广州嘉越医药科技有限公司 | 一种吡啶衍生物、中间体、制备方法和应用 |
WO2023232838A1 (fr) | 2022-05-31 | 2023-12-07 | Janssen Pharmaceutica Nv | Bédaquiline destinée à être utilisée dans le traitement de la lèpre |
WO2024068693A1 (fr) | 2022-09-28 | 2024-04-04 | Janssen Pharmaceutica Nv | Formulations à action prolongée |
WO2024068699A1 (fr) | 2022-09-28 | 2024-04-04 | Janssen Pharmaceutica Nv | Formulations à action prolongée |
WO2024089170A1 (fr) | 2022-10-27 | 2024-05-02 | Janssen Sciences Ireland Unlimited Company | Composés antibactériens |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2270123A1 (fr) * | 1996-10-28 | 1998-05-07 | Department Of The Army, U.S. Government | Composes, compositions et techniques afferentes, aux fins du traitement d'infections resistant aux antibiotiques |
US6103905A (en) * | 1997-06-19 | 2000-08-15 | Sepracor, Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
HUP0003364A3 (en) * | 1997-06-19 | 2002-03-28 | Sepracor Inc Marlborough | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
AU6645198A (en) * | 1998-01-23 | 1999-08-09 | Fire Armour Pte Ltd | Nozzle with axially and perpendicularly directed apertures |
AU2717899A (en) * | 1998-01-26 | 1999-08-09 | Smithkline Beecham Plc | Quinoline derivatives as antibacterials |
US6819431B2 (en) * | 2001-07-06 | 2004-11-16 | Zygo Corporation | Polymer retarder |
EE05394B1 (et) * | 2004-12-24 | 2011-04-15 | Janssen Pharmaceutica N.V. | Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis |
CA2528849C (fr) * | 2005-06-08 | 2014-01-14 | Janssen Pharmaceutica N.V. | Derives de quinoleine utilises comme agents antibacteriens |
-
2003
- 2003-07-18 PL PL375523A patent/PL222801B1/pl unknown
- 2003-07-18 DK DK03771115.7T patent/DK1527050T3/da active
- 2003-07-18 NZ NZ538391A patent/NZ538391A/en not_active IP Right Cessation
- 2003-07-18 RS YU20050058A patent/RS52431B/en unknown
- 2003-07-18 CA CA2493225A patent/CA2493225C/fr not_active Expired - Lifetime
- 2003-07-18 SI SI200332211T patent/SI2301544T1/sl unknown
- 2003-07-18 BR BRPI0312927A patent/BRPI0312927B8/pt not_active IP Right Cessation
- 2003-07-18 SI SI200331819T patent/SI1527050T1/sl unknown
- 2003-07-18 EP EP03771115A patent/EP1527050B1/fr not_active Expired - Lifetime
- 2003-07-18 KR KR1020057000447A patent/KR100733577B1/ko active Protection Beyond IP Right Term
- 2003-07-18 EA EA200500257A patent/EA008937B1/ru active Protection Beyond IP Right Term
- 2003-07-18 PT PT03771115T patent/PT1527050E/pt unknown
- 2003-07-18 DK DK10154018.5T patent/DK2301544T3/da active
- 2003-07-18 CN CN2007101049477A patent/CN101070304B/zh not_active Expired - Lifetime
- 2003-07-18 AU AU2003262529A patent/AU2003262529B2/en not_active Expired
- 2003-07-18 MX MXPA05001052A patent/MXPA05001052A/es active IP Right Grant
- 2003-07-18 UA UAA200501778A patent/UA82198C2/uk unknown
- 2003-07-18 ES ES10154018T patent/ES2395237T3/es not_active Expired - Lifetime
- 2003-07-18 CN CNB038177137A patent/CN1325475C/zh not_active Expired - Lifetime
- 2003-07-18 WO PCT/EP2003/050322 patent/WO2004011436A1/fr active IP Right Grant
- 2003-07-18 EP EP10154018A patent/EP2301544B1/fr not_active Expired - Lifetime
- 2003-07-18 PT PT101540185T patent/PT2301544E/pt unknown
- 2003-07-18 DE DE60332023T patent/DE60332023D1/de not_active Expired - Lifetime
- 2003-07-18 AP AP2005003210A patent/AP2421A/xx active
- 2003-07-18 JP JP2004523812A patent/JP4484703B2/ja not_active Expired - Lifetime
- 2003-07-18 AT AT03771115T patent/ATE463482T1/de active
- 2003-07-18 ES ES03771115T patent/ES2343458T3/es not_active Expired - Lifetime
- 2003-07-18 ME MEP-2008-92A patent/ME00131B/fr unknown
- 2003-07-24 TW TW092120160A patent/TWI323730B/zh active
- 2003-07-24 MY MYPI20032793A patent/MY143564A/en unknown
- 2003-07-24 AR AR20030102655A patent/AR040673A1/es active IP Right Grant
-
2004
- 2004-12-08 US US11/007,026 patent/US7498343B2/en active Active
- 2004-12-29 IS IS7620A patent/IS2914B/is unknown
-
2005
- 2005-01-17 HR HRP20050045AA patent/HRP20050045B1/hr not_active IP Right Cessation
- 2005-01-24 IL IL166457A patent/IL166457A/en active IP Right Grant
- 2005-01-24 ZA ZA200500680A patent/ZA200500680B/xx unknown
- 2005-01-27 NO NO20050476A patent/NO329935B1/no not_active IP Right Cessation
-
2006
- 2006-03-17 HK HK06103424A patent/HK1083496A1/xx not_active IP Right Cessation
-
2008
- 2008-04-09 HK HK08103990.6A patent/HK1113795A1/xx not_active IP Right Cessation
-
2009
- 2009-12-10 IL IL202655A patent/IL202655A/en active IP Right Grant
-
2010
- 2010-07-07 CY CY20101100634T patent/CY1111882T1/el unknown
-
2012
- 2012-02-28 HR HRP20120190AA patent/HRP20120190B1/hr not_active IP Right Cessation
- 2012-12-19 CY CY20121101241T patent/CY1113497T1/el unknown
-
2014
- 2014-08-14 HU HUS1400047C patent/HUS1400047I1/hu unknown
- 2014-08-14 BE BE2014C051C patent/BE2014C051I2/nl unknown
- 2014-08-14 CY CY2014033C patent/CY2014033I2/el unknown
- 2014-08-14 LU LU92520C patent/LU92520I2/fr unknown
- 2014-08-14 NL NL300684C patent/NL300684I2/nl unknown
- 2014-08-18 FR FR14C0060C patent/FR14C0060I2/fr active Active
- 2014-08-20 NO NO2014021C patent/NO2014021I1/no not_active IP Right Cessation